

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1	1	Web Page for STN Seminar Schedule - N. America
NEWS 2	2	AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 3	3	AUG 06 FSTA enhanced with new thesaurus edition
NEWS 4	4	AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	5	AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	6	AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	7	AUG 27 USPATOLD now available on STN
NEWS 8	8	AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	9	SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	10	SEP 13 FORIS renamed to SOFIS
NEWS 11	11	SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 12	12	SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	13	SEP 17 CAplus coverage extended to include traditional medicine patents
NEWS 14	14	SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	15	OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	16	OCT 19 BEILSTEIN updated with new compounds
NEWS 17	17	NOV 15 Derwent Indian patent publication number format enhanced
NEWS 18	18	NOV 19 WPIX enhanced with XML display format
NEWS 19	19	NOV 30 ICSD reloaded with enhancements
NEWS 20	20	DEC 04 LINPADOCDB now available on STN
NEWS 21	21	DEC 14 BEILSTEIN pricing structure to change
NEWS 22	22	DEC 17 USPATOLD added to additional database clusters
NEWS 23	23	DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 24	24	DEC 17 DGENE now includes more than 10 million sequences
NEWS 25	25	DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	26	DEC 17 MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	27	DEC 17 CA/CAplus enhanced with new custom IPC display formats
NEWS 28	28	DEC 17 STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	29	JAN 02 STN pricing information for 2008 now available
NEWS 30	30	JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	31	JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32	32	JAN 28 MARPAT searching enhanced
NEWS 33	33	JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 34	34	JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35	35	JAN 28 MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:29:30 ON 04 FEB 2008

FILE 'REGISTRY' ENTERED AT 11:29:39 ON 04 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3
DICTIONARY FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10566799.str
```



```

chain nodes :
7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 26 27 28 29 30 31 32
 33 34
ring nodes :
1 2 3 4 5 6
chain bonds :
1-15 2-22 2-23 3-24 4-7 5-25 6-20 6-21 7-8 7-14 8-9 8-12 8-13 9-10
9-11 15-34 26-27 26-28 26-29 30-31 31-32 31-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-14 9-10 9-11 15-34 26-27 26-28 26-29
30-31 31-32 31-33
exact bonds :
1-15 2-22 2-23 3-24 5-25 6-20 6-21 7-8 8-9 8-12 8-13
isolated ring systems :
containing 1 :

```

G1:H,Ak

G2:[*1], [*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS
31:CLASS 32:CLASS 33:CLASS 34:CLASS

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 11:30:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 883 TO ITERATE

100.0% PROCESSED 883 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 15878 TO 19442
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 11:30:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 17061 TO ITERATE

100.0% PROCESSED 17061 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.36 178.57

STN INTERNATIONAL LOGOFF AT 11:30:10 ON 04 FEB 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1			Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06		CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06		FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13		CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20		CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27		Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27		USPATOLD now available on STN
NEWS 8	AUG 28		CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07		STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13		FORIS renamed to SOFIS
NEWS 11	SEP 13		INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17		CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17		CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24		EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02		CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19		BEILSTEIN updated with new compounds
NEWS 17	NOV 15		Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19		WPIX enhanced with XML display format
NEWS 19	NOV 30		ICSD reloaded with enhancements
NEWS 20	DEC 04		LINPADOCDB now available on STN
NEWS 21	DEC 14		BEILSTEIN pricing structure to change
NEWS 22	DEC 17		USPATOLD added to additional database clusters
NEWS 23	DEC 17		IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17		DGENE now includes more than 10 million sequences
NEWS 25	DEC 17		TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17		MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17		CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17		STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02		STN pricing information for 2008 now available
NEWS 30	JAN 16		CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28		USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32	JAN 28		MARPAT searching enhanced
NEWS 33	JAN 28		USGENE now provides USPTO sequence data within 3 days of publication
NEWS 34	JAN 28		TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35	JAN 28		MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:31:50 ON 04 FEB 2008

FILE 'REGISTRY' ENTERED AT 11:31:59 ON 04 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3
DICTIONARY FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10566799a.str
```



chain nodes :

7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 26 27 28 29 30 31 32
33 34 40 41 42 43

ring nodes :

1 2 3 4 5 6 38 39

chain bonds :

1-15 2-22 2-23 3-24 4-7 5-25 6-20 6-21 7-8 7-14 8-9 8-12 8-13 9-10
9-11 15-34 26-27 26-28 26-29 30-31 31-32 31-33 38-40 38-41 39-42 39-43

ring bonds :

1-2 1-6 2-3 3-4 3-39 4-5 5-6 5-38 38-39

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-14 9-10 9-11 15-34 26-27 26-28 26-29
30-31 31-32 31-33

exact bonds :

1-15 2-22 2-23 3-24 3-39 5-25 5-38 6-20 6-21 7-8 8-9 8-12 8-13 38-39
38-40 38-41 39-42 39-43

isolated ring systems :

containing 1 :

G1:H, Ak

G2:[*1], [*2]

Match level :

1:Atom	2:Atom	3:Atom	4:Atom	5:Atom	6:Atom	7:CLASS	8:CLASS	9:CLASS	10:CLASS
11:Atom	12:CLASS	13:CLASS	14:CLASS	15:CLASS	20:CLASS	21:CLASS	22:CLASS		
23:CLASS	24:CLASS	25:CLASS	26:CLASS	27:CLASS	28:CLASS	29:CLASS	30:CLASS		
31:CLASS	32:CLASS	33:CLASS	34:CLASS	38:Atom	39:Atom	40:CLASS	41:CLASS		
42:CLASS	43:CLASS								

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 11:32:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED	21 ITERATIONS	0 ANSWERS
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS:	ONLINE **COMPLETE**
	BATCH **COMPLETE**

PROJECTED ITERATIONS:	146 TO 694
-----------------------	-------------------

PROJECTED ANSWERS:	0 TO 0
--------------------	---------------

L2 0 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 11:32:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 451 TO ITERATE

100.0% PROCESSED	451 ITERATIONS	0 ANSWERS
SEARCH TIME: 00.00.01		

L3 0 SEA SSS FUL L1

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.36	178.57

STN INTERNATIONAL LOGOFF AT 11:32:28 ON 04 FEB 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1	1	Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32	JAN 28	MARPAT searching enhanced
NEWS 33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:34:40 ON 04 FEB 2008

FILE 'REGISTRY' ENTERED AT 11:34:51 ON 04 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3
DICTIONARY FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3

New CAS Information Use Policies. enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10566799c.str



```

chain nodes :
7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 28 29 30 31 32
ring nodes :
1 2 3 4 5 6 26 27
chain bonds :
1-15 2-22 2-23 3-24 4-7 5-25 6-20 6-21 7-8 7-14 8-9 8-12 8-13 9-10
9-11 15-32 26-28 26-29 27-30 27-31
ring bonds :
1-2 1-6 2-3 3-4 3-27 4-5 5-6 5-26 26-27
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-14 9-10 9-11 15-32
exact bonds :
1-15 2-22 2-23 3-24 3-27 5-25 5-26 6-20 6-21 7-8 8-9 8-12 8-13 26-27
26-28 26-29 27-30 27-31
isolated ring systems :
containing 1 :

```


G1:H,Ak

G2:S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:Atom 27:Atom 28:CLASS 29:CLASS 30:CLASS
31:CLASS 32:CLASS

L1 STRUCTURE uploaded

=> d 11
L1 HAS NO ANSWERS
L1 STR



G1 H, Ak

G2 S, N

Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 11:35:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2671 TO 4249
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 11:35:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3521 TO ITERATE

100.0% PROCESSED 3521 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

STN INTERNATIONAL LOGOFF AT 11:35:18 ON 04 FEB 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1			Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06		CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06		FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13		CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20		CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27		Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27		USPATOLD now available on STN
NEWS 8	AUG 28		CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07		STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13		FORIS renamed to SOFIS
NEWS 11	SEP 13		INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17		CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17		CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24		EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02		CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19		BEILSTEIN updated with new compounds
NEWS 17	NOV 15		Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19		WPIX enhanced with XML display format
NEWS 19	NOV 30		ICSD reloaded with enhancements
NEWS 20	DEC 04		LINPADOCDB now available on STN
NEWS 21	DEC 14		BEILSTEIN pricing structure to change
NEWS 22	DEC 17		USPATOLD added to additional database clusters
NEWS 23	DEC 17		IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17		DGENE now includes more than 10 million sequences
NEWS 25	DEC 17		TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17		MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17		CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17		STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02		STN pricing information for 2008 now available
NEWS 30	JAN 16		CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28		USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32	JAN 28		MARPAT searching enhanced
NEWS 33	JAN 28		USGENE now provides USPTO sequence data within 3 days of publication
NEWS 34	JAN 28		TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35	JAN 28		MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:41:19 ON 04 FEB 2008

FILE 'REGISTRY' ENTERED AT 11:41:29 ON 04 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3
DICTIONARY FILE UPDATES: 3 FEB 2008 HIGHEST RN 1001389-12-3

New CAS Information Use Policies. enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10566799.str
```



chain nodes :

7 8 9 10 11 12 13 14 15 20 21 22 23 24 25 26 28

ring nodes :

1 2 3 4 5 6

chain bonds :

1-15 1-28 2-22 2-23 3-24 4-7 5-25 6-20 6-21 7-8 7-14 8-9 8-12 8-13
9-10 9-11 15-26

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-14 9-10 9-11 15-26

exact bonds :

1-15 1-28 2-22 2-23 3-24 5-25 6-20 6-21 7-8 8-9 8-12 8-13

isolated ring systems :

containing 1 :

G1:H,Ak


G2:S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR



G1 H, Ak
G2 S, N

Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 11:41:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 14395 TO ITERATE

13.9% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 280713 TO 295087
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 11:41:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 284933 TO ITERATE

100.0% PROCESSED 284933 ITERATIONS 37 ANSWERS
SEARCH TIME: 00.00.04

L3 37 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
178.36 178.57

FILE 'CAPLUS' ENTERED AT 11:42:04 ON 04 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Feb 2008 VOL 148 ISS 6
FILE LAST UPDATED: 3 Feb 2008 (20080203/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 full
L4 14 L3

=> d ibib abs hitstr tot

ACCESSION NUMBER: 20071395785 CAPLUS

DOCUMENT NUMBER: 148:55084

TITLE: Preparation of pyrazolopyrimidines as

cyclin-dependent

kinase inhibitors

INVENTOR(S): Guz, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labrol, Marc; Keertikar, Kartik M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 497pp., Cont.-in-part of U.S.

Ser. No. 710,644.

CODEN: USXXCO

DOCUMENT TYPE:

Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007281951	A1	20071206	US 2007-788856	20070420
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 2007037824	A1	20070215		
US 2004209878	A1	20041021	US 2004-776988	20040211
US 7119200	B2	20061010		
US 2006128725	A1	20060615	US 2005-245401	20051006
US 7196078	B2	20070327		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
US 2007225270	A1	20070927	US 2007-710644	20070223
			US 2002-408027P	P 20020904

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 148:55084
GI

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the


CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I, alone or in combination with other therapeutic agent, is claimed.

IT 67726-93-0
RN 67726-93-0 CAPLUS
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

RN 67726-93-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[(1-(3-phenylbutyl)-4-piperidinyl)methyl]- (CA INDEX NAME)



ACCESSION NUMBER: 20071359039 CAPLUS

DOCUMENT NUMBER: 146:379835

TITLE: Preparation of cyanopyridones as survivin inhibitors

INVENTOR(S): Wendt, Michael D.; Sun, Chachong; Sauer, Daryl R.; Elmore, Steven W.; Kunzer, Aaron R.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007072833	A1	20070329	US 2006-529845	20060929
PRIORITY APPLN. INFO.:			US 2005-721634P	P 20050929

OTHER SOURCE(S): MARPAT 146:379835

GI



AB Title compds. (I; A1, B1 = R1, OR1, SOR1, SO2R1, COR1, CO2R1, NHCOR1, SO2NHR1, NHSO2NHR1, etc.; R1 = (fused) Ph, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, (substituted) alkyl, alkenyl, alkynyl, were prepared. Thus, 5-bromo-2-hydroxyacetophenone,

4-methylbenzaldehyde, Et₂o, cyanoacetate, and ammonium acetate were refluxed together in EtOH for 6 h to give

6-(5-bromo-2-hydroxyphenyl)-4-(4-methylphenyl)-2-oxo-1,2-dihydro-3-pyridinecarboxonitrile. I bound to survivin with binding affinities of 0.037-29 μ M.

IT 931113-30-3

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of cyanopyridones as survivin inhibitors)

RN 931113-30-3 CAPLUS

CN 4-Piperidinecarboxamide, N-[(5-chloro-3-(4-(2-chloro-5-(trifluoromethyl)phenyl)-5-cyano-1,6-dihydro-6-oxo-2-pyridinyl)-2-hydroxyphenyl)methyl]-N-methyl-1-[3-(5-methyl-2-furanyl)butyl]- (CA INDEX NAME)

INDEX

NAME)



PAGE 1-A

PAGE 1-B

CF₃

L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:579598 CAPLUS
 DOCUMENT NUMBER: 145:62916
 TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Lebrol, Marc; Keertikar, Kartik M.
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 1068 pp., Cont.-in-part of

Ser. No. 776,988.

CODEN: USXXCO

Patent



Language: English

Family Acc. Num. Count: 7


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006128725	A1	20060615	US 2005-245401	20051006
US 7196078	B2	20070327		
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 2007037824	A1	20070215		
US 2004209878	A1	20041021	US 2004-776988	20040211
US 7113200	B2	20061010		
ZA 200501855	A	20060329	ZA 2005-1855	20060117
US 2007072981	A1	20070329	US 2006-542920	20061004
WO 2007044449	A2	20070419	WO 2006-US38939	20061004
WO 2007044449	A3	20070524		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HM, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KW, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MC, MN, MM, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TR, TN, TT, TZ, UG, VN, ZA, ZM, ZW, RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 200725270	A1	20070927	US 2007-710644	20070223
US 2007281951	A1	20071206	US 2007-788856	20070420
PRIORITY APPLN. INFO.:			US 2002-408027P	P 20020904
			US 2002-421959P	P 20021029
			US 2003-654546	A2 20030903
			US 2004-776988	A2 20040211
			CN 2003-824997	A3 20030903
			US 2005-245401	A2 20051006
			US 2007-710644	A2 20070223

OTHER SOURCE(S): MARPAT 145:62916
 GI



III



AB The title compds. (I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl), useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the

CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed.


IT 677286-93-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

for treating cancer)

RN 677286-93-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[(1-(3-phenylbutyl)-4-piperidinyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:981365 CAPLUS
 DOCUMENT NUMBER: 141:379943
 TITLE: Preparation of pyrazolopyrimidines as
 cyclin-dependent kinase inhibitors
 INVENTOR(S): Guz, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;
 Doll, Ronald J.; Girijavallabhan, Viyyoor M.;
 Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.;
 Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent;
 Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas
 Walsh

PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
 SOURCE: U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of
 U.S.

Ser. No. 654,546.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209878	A1	20041021	US 2004-776988	20040211
US 2004209878	A1	20041021	US 2004-776988	20040211
PRIORITY APPLN. INFO.:			US 2002-408027P	P 20020904
			US 2002-421959P	P 20021029
			US 2003-654546	A2 20030903
			US 2004-776988	A 20040211

GI

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminopyrimidine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a part

III of I-III series.

IT 677286-93-0P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)


(preparation of pyrazolopyrimidines as cyclin-dependent kinase

inhibitors for treating cancer)

RN 677286-93-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[(1-(3-phenylbutyl)-4-piperidinyl)methyl]- (CA INDEX NAME)

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:546499 CAPLUS

DOCUMENT NUMBER: 141:106377

TITLE: A preparation of novel piperidine derivatives as modulators of chemokine receptor CCR5

INVENTOR(S): Oldfield, John; Tucker, Howard

PATENT ASSIGNEE(S): AstraZeneca Ab, Swed.

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2004056808	A1	20040708	WO 2003-SE2005	20031218	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SU, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD					
TG	AU 2003288853	A1	20040714	AU 2003-288853	20031218
EP 1572683	A1	20050914	EP 2003-781232	20031218	
EP 1572683	B1	20061018			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006512364	T	20060413	JP 2004-562206	20031218	
AT 342898	T	20061115	AT 2003-781232	20031218	
ES 2274295	T3	20070516	ES 2003-781232	20031218	
US 2006069120	A1	20060330	US 2005-539522	20050617	
			SE 2002-3820	A 20021220	
				WO 2003-SE2005	
				W 20031218	

OTHER SOURCE(S): MARPAT 141:106377
 GI



AB The invention relates to a preparation of novel piperidine derivs. of formula I (wherein: A is absent or $(CH_2)_2$; R1 is alkyl, $C(O)NH$ -alkyl, or CO_2 -alkyl, etc.; R2 is alkyl, Ph, heteroaryl, or cycloalkyl; R3 is H or alkyl; R4 is (hetero)aryl; R5 is H or alkyl; X is $(CH_2)_1-2$, $CH:CH$, OCH_2 , or $S(O)O-2CH_2$, useful as modulators of chemokine receptor CCR5. The invention compds. are claimed to be useful for the treatment of CCR5-mediated diseases such as autoimmune, inflammatory, or proliferative diseases. The ability of the invention compds. to inhibit the binding of RANTES and MIP-1 α was assessed (certain compds. of formula I have IC50 < 50 μM). For instance, Pic50 (neg. log of the IC50 result) for piperidine derivative II was determined as 7.92 (MIP-1 α binding inhibition).


IT 718637-43-5
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of novel piperidine derivs. as modulators of chemokine receptor CCR5)

RN 718637-51-5 CAPLUS

CN 4-Piperidineacetamide, N-(4-fluorophenyl)-1-[(3S)-3-hydroxy-3-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 2004:546479 CAPLUS

DOCUMENT NUMBER: 141:106374

TITLE: A preparation of novel piperidine derivatives as modulators of chemokine receptor CCR5

INVENTOR(S): Cumming, John; Faull, Alan; Fielding, Colin; Oldfield,

John; Tucker, Howard

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.

SOURCE: PCT Int. Appl. 118 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056773	A1	20040708	WO 2003-SE2008	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508624	A1	20040708	CA 2003-2508624	20031218
AU 2003288856	A1	20040714	AU 2003-288856	20031218
EP 2005272650	A1	20050914	EP 2003-781235	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017459	A	20051116	BR 2003-17459	20031218
CN 1732153	A	20060208	CN 2003-80107833	20031218
JP 2006514107	T	20060427	JP 2005-502630	20031218
IN 2005DN02442	A	20070406	IN 2005-DN2442	20050607
MX 2005PA06381	A	20050829	MX 2005-PA6381	20050614
US 2006189650	A1	20060824	US 2005-539859	20050617
NO 2005003539	A	20050920	NO 2005-3539	20050719
ZA 2005004616	A	20060329	ZA 2005-4616	20060116
PRIORITY APPLN. INFO.:			SE 2002-3821	A 20021220
			SE 2003-499	A 20030224
			SE 2003-1425	A 20030515
			WO 2003-SE2008	W 20031218

OTHER SOURCE(S): MARPAT 141:106374
GI



IT 718637-43-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of novel piperidine derivs. as modulators of chemokine receptor CCR5)
RN 718637-43-5 CAPLUS
CN 4-Piperidineacetamide, N-(4-chloro-3-phenylpropyl)-N-(4-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT



AB The invention relates to a preparation of novel piperidine derivs. of formula I (wherein: A is absent or $(CH_2)_2$; R1 is alkyl, $C(O)NH$ -alkyl, or CO_2 -alkyl, etc.; R2 is alkyl, Ph, heteroaryl, or cycloalkyl; R3 is H or alkyl; R4 is (hetero)aryl or (cyclo)alkyl; R5 is H or S(O)O-2; useful as modulators of chemokine receptor CCR5. The invention compds. are claimed to be useful for the treatment of CCR5-mediated diseases such as autoimmune, inflammatory, or proliferative diseases. The invented compds. are also


of value in inhibiting the entry of viruses (such as HIV) into target cells (no biol. data). The ability of the invention compds. to inhibit the binding of RANTES and MIP-1 α was assessed (certain compds. of formula I have IC50 < 50 μM). For instance, Pic50 (neg. log of the IC50 result) for piperidine derivative II was determined as 6.91 (table XV).

IT 718610-18-5P 718611-68-8P 718611-69-9P
718611-70-2P 718611-71-3P 718611-72-4P
718611-73-5P 718612-04-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel piperidine derivs. as modulators of chemokine receptor


ccr5)
RN 718610-18-5 CAPLUS
CN Benzanilide,
4-chloro-N-[(1S)-3-{4-[2-[(4-methylsulfonyl)phenyl]sulfonyl]ethyl}-1-piperidinyl]-1-phenylpropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-68-8 CAPLUS
 CN Propanamide, 3,3,3-trifluoro-N-[(1S)-3-[4-[2-[(4-methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-69-9 CAPLUS
 CN Propanamide, 3,3,3-trifluoro-N-[(1S)-3-[4-[2-[(4-methylphenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-70-2 CAPLUS
 CN Propanamide, 3,3,3-trifluoro-N-[(1S)-3-[4-[2-[(4-fluorophenyl)sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-71-3 CAPLUS
 CN Butanamide, 4,4-trifluoro-N-[(1S)-3-[4-[2-[(4-methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-72-4 CAPLUS
 CN Cyclobutanecarboxamide, 3,3-difluoro-N-[(1S)-3-[4-[2-[(4-methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718611-73-5 CAPLUS
 CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-[2-[(4-methylsulfonyl)phenyl]sulfonyl]ethyl]-1-piperidinyl]-1-phenylpropyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 718612-04-5 CAPLUS
 CN Cyclohexanecarboxamide, 4,4-difluoro-N-[(1S)-3-[4-[(4-methylsulfonyl)phenyl]methyl]-1-piperidinyl]-1-phenylpropyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 718610-15-2P 718610-19-6P 718610-23-2P
 718610-66-3P 718610-69-6P 718611-16-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of novel piperidine derivs. as modulators of chemokine receptor ccr5)

RN 718610-15-2 CAPLUS
 CN Piperidine, 1-(3-chloro-3-phenylpropyl)-4-(2-[(4-methylsulfonyl)phenyl]sulfonyl)ethyl- (CA INDEX NAME)




RN 718610-19-6 CAPLUS
 CN 1-Piperidinopropanamine, 4-(2-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl)- α -phenyl-, (aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 718610-23-2 CAPLUS
 CN Piperidine, 1-(3-chloro-3-phenylpropyl)-4-(2-[(4-fluorophenyl)sulfonyl]ethyl)- (CA INDEX NAME)




RN 718610-66-3 CAPLUS
 CN 1-Piperidinopropanol, 4-(2-[(4-methylsulfonyl)phenyl]sulfonyl)ethyl- α -phenyl-




RN 718610-69-6 CAPLUS
 CN 1-Piperidinopropanol, 4-(2-[(4-fluorophenyl)sulfonyl]ethyl)- α -phenyl-, (aS)- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN Carbanic acid.
 [(1S)-3-(4-[(4-(methylsulfonyl)phenyl)sulfonyl]ethyl)-1-piperidinyl]-1-phenylpropyl-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 ACESSION NUMBER: 2004:265849 CAPLUS
 DOCUMENT NUMBER: 140:321371
 TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
 INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Parakar, Vidyadhar M.; Hobbs, Douglas Walsh

PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 609 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English




FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022561	A1	20040318	WO 2003-XB27555	20030903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, RW: GH, GM, KE, LG, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, BE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1735614	A	20060215	CN 2003-824997	20030903
CN 1880317	A	20061220	CN 2006-10101322	20030903
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
PRIORITY APPLN. INFO.:			US 2002-408027P	P 20020904
			US 2002-421959P	P 20021029
			CN 2003-824997	A3 20030903

GI

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB The title compds. II R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the

CDKs such as cancer, were prepared. Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μ M and 0.029 μ M against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This

is a Part

III of I-III series.

IT 677286-93-0P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase


inhibitors

for treating cancer)

RN 677286-93-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-bromo-5-(2-chlorophenyl)-N-[(1-(3-phenylbutyl)-4-piperidinyl)methyl]- (CA INDEX NAME)

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002-754342 CAPLUS
 DOCUMENT NUMBER: 137:263068
 TITLE: Preparation of aryl and biaryl derivatives having
 Melanin-concentrating hormone modulatory activity
 INVENTOR(S): Hobbs, Douglas W.; Guo, Tao; Hunter, Rachael C.; Gu,
 Huizhong
 PATENT ASSIGNEE(S): Pharmacopeia, Inc., USA
 SOURCE: PCT Int. Appl., 180 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076929	A1	20021003	WO 2002-US8300	20020319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MX, MN, MK, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW				
AT: BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2441235	A1	20021003	CA 2002-2441235	20020319
AU 2002247367	A1	20021008	AU 2002-247367	20020319
US 2003092715	A1	20030515	US 2002-101136	20020319
US 7034056	B2	20060425		
EP 1370520	A1	20031217	EP 2002-715150	20020319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1498205	A	20040519	CN 2002-806895	20020319
HU 2004000252	A2	20040830	HU 2004-252	20020319
JP 2004526736	T	20040902	JP 2002-576192	20020319
NZ 527680	A	20050729	NZ 2002-527680	20020319
ZA 2003006727	A	20041129	ZA 2003-6727	20030828
MX 2003PA08484	A	20031208	MX 2003-PA8484	20030919
			US 2001-277534P	P 20010321
PRIORITY APPLN. INFO.:				
		WO 2002-US8300		W 20020319

OTHER SOURCE(S): MARPAT 137:263068
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I; A = (un)substituted aryl, pyridinyl, pyrazinyl, pyridazinyl, Z = biphenylcarbamoyl, biphenylcarbonyl, biphenoxycarbonyl, biphenylsulfonyl; M = H, Me, Et, iso-Pr, n-Pr, cyclobutyl; n = 2-4; p = 1-6; R1 = NH2, NHR, NOR2, NH(CH2)nNR2; R = Me, Et, n-Pr, iso-Pr, cyclobutyl; R2 = H, alkyl are prepared as antagonists of the Melanin-concentrating hormone (MCH) receptor. In one embodiment, this invention provides methods of preparing title compds., pharmaceutical compns. containing one or more of title compds., methods of preparing pharmaceutical

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:177400 CAPLUS
 DOCUMENT NUMBER: 135:5510
 TITLE: Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors
 AUTHOR(S): Ting, P. C.; Lee, J. F.; Anthes, J. C.; Shih, N.-Y.; Piwinski, J. J.
 CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033-1300, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(4), 491-494
 CODEN: BMCLB; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:5510
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4(Z)-(methoxyimino)pentyl-1-piperidines, e.g. I and II, were prepared the their NK1 and NK2 receptor activity was evaluated. Compds. I and II were among 5 of the most potent inhibitors. A series of 4(Z)-(methoxyimino)pentyl-1-piperidines was prepared, and their biol. activity as dual NK1/NK2 receptor antagonists determined
 IT 340962-38-1P 340962-41-6P 340962-43-8P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors)
 RN 340962-38-1 CAPLUS
 CN 4-Piperidinecarboxamide,
 1-[(4Z)-5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4-(methoxyimino)pentyl]- (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 formulations comprising one or more title compds., and methods of treatment, prevention or amelioration or one or more of diseases assoc'd. with the MCH receptor. Thus, the title compd. II was an illustrative inventive compd.
 IT 463940-44-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aryl and biaryl derivs. having Melanin-concentrating hormone modulatory activity)


RN 463940-44-5 CAPLUS
 CN Benzamide, N-(2-(3,4-dichlorophenyl)-4-[(4-((3,4-dichlorophenyl)amino)methyl)-1-piperidinyl]butyl)-3-bis(trifluoromethyl)- (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A





PAGE 2-A




RN 340962-41-6 CAPLUS
 CN Benzamide,
 N-((1-(4Z)-5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4-(methoxyimino)pentyl)-4-piperidinyl)methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A

REFERENCE COUNT:
THIS11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

PAGE 2-A



RN 340962-43-8 CAPLUS
 CN 2-Pentanone, 1-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-5-[(1-((hydroxymethyl)cyclopentyl)amino)methyl]-1-piperidinyl-, 6-methyloxime, (2Z)- (CA INDEX NAME)

Double bond geometry as shown.

ACCESSION NUMBER: 1999:659363 CAPLUS

DOCUMENT NUMBER: 131:271485

TITLE: Preparation of biocidal benzylbiphenyl derivatives
Meerpoel, Lieven; Van Der Flaas, Mark Arthur Josepha;INVENTOR(S): Van Der Veken, Louis Jozef Elisabeth; Heeres, Jan
Janssen Pharmaceutica N.V., Belg.

PATENT ASSIGNEE(S): PCT Int. Appl. 52 pp.

SOURCE: CODEN: PIXDD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951578	A1	19991014	WO 1999-EP2098	19990325
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MM, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 245763	B	20051221	TW 1999-88103906	19990315
CA 2326159	A1	19991014	CA 1999-2326159	19990325
AU 9933325	A	19991025	AU 1999-33325	19990325
AU 759157	B2	20030410		
BR 9909344	A	20001212	BR 1999-9344	19990325
EP 1066259	A1	20010110	EP 1999-914550	19990325
EP 1066259	B1	20070110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200002846	T2	20010122	TR 2000-2846	19990325
JP 2002510677	T	20020409	JP 2000-542299	19990325
CN 1110478	B	20030604	CN 1999-804494	19990325
NZ 507024	A	20030725	NZ 1999-507024	19990325
RU 2218333	C2	20031210	RU 2000-127229	19990325
IL 138736	A	20050831	IL 1999-138736	19990325
PL 193580	B1	20070228	PL 1959-3432	19990325
ES 2280117	T3	20070901	ES 1999-914550	19990325
US 6440440	B1	20020827	US 2000-647015	20000922
ZA 2000005237	A	20010928	ZA 2000-5237	20000928
IN 2000WN00450	A	20050318	IN 2000-M0450	20000928
NO 2000004905	A	20000929	NO 2000-4905	20000929
NO 317784	B1	20041213		
MX 2000PA09617	A	20010405	MX 2000-PA9617	20000929
PRIORITY APPLN. INFO.:			EP 1998-201043	A 19980402
				WO 1999-EP2098
				W 19990325

OTHER SOURCE(S): MARPAT 131:271485
GI

AB The title compds. I (dotted line is an optional bond; X is a direct bond when the dotted line represents a bond, or X is hydrogen or hydroxy, when the dotted line does not represent a bond; R1, R2, R5 and R6 are each independently selected from hydrogen, halo, hydroxy, Cl-alkyl, Cl-4alkyloxy, -SO3H, etc.; R3 and R4 are each independently selected from hydrogen, halo, hydroxy, Cl-alkyl, Cl-4alkyloxy, nitro, amino, trifluoromethyl, or trifluoromethoxy; L is a radical of formula Q, Q1, etc.), biocides, were prepared e.g., 4-[(1,1'-biphenyl)-4-yl](4-fluorophenyl)methylene(1,1'-bipiperidine) dihydrochloride was prepared. Biocidal activities of I were tested toward bacteria, e.g. E. coli, and yeast.

IT 245551-86-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of biocidal benzylbiphenyl derivs.)

RN 245551-86-4 CAPLUS
 CN 1-Piperidinepropanol, α -1,1'-biphenyl)-4-yl- α -(2,4-dichlorophenyl)-4-(2-(dimethylamino)ethyl)- dihydrochloride (9Cl) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



●2 HCl

DOCUMENT NUMBER: 131:199712
TITLE: Preparation of heterocyclic compounds as glycine transport inhibitors
INVENTOR(S): Luyten, Walter Herman Maria Louis; Janssens, Frans Edward; Kennis, Ludo Edmond Josephine
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIIXD2


DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945011	A1	19990910	WO 1999-BP1308	19990226
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, S2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2322136	A1	19990910	CA 1999-2322136	19990226
AU 9932544	A	19990920	AU 1999-32544	19990226
BR 9907953	A	20001024	BR 1999-7953	19990226
EP 1058684	A1	20001213	EP 1999-937930	19990226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, PT, IE, SI, LT, LV, FI, RO				
TR 200002570	T2	20001221	TR 2000-2570	19990226
HU 2001001281	A2	20010928	HU 2001-1281	19990226
HU 2001001281	A3	20011128		
EE 20000483	A	20020215	EE 2000-483	19990226
JP 2002505332	T	20020219	JP 2000-534553	19990226
IN 2000M00192	A	20050304	IN 2000-MN192	20000718
HR 2000000524	A1	20010228	HR 2000-524	20000802
BG 104686	A	20010430	BG 2000-104686	20000811
NO 2000004432	A	20001102	NO 2000-4432	20000905
MX 2000PA08692	A	20010328	MX 2000-PAB692	20000905
PRIORITY APPLN. INFO.:			EP 1998-200700	A 19980306
			WO 1999-EP1308	W 19990226

OTHER SOURCE(S): MARPAT 131:199712
GI




AB The present invention is concerned with the use of glycine transport inhibiting α,ω -diphenyl-1-piperidinebutanamides for the preparation of medicaments, title compds. I (R1, R2 = H, alkyl; X = CR4R5; R4 = H, OH, etc.; R5 = diarylmethoxyalkyl, etc) for treating disorders of the central and peripheral nervous system, in particular psychoses, pain, epilepsy, neurodegenerative diseases (Alzheimer's disease), stroke, head trauma, multiple sclerosis and the like. The title compound II was prepared. Formulations are given. The invention further comprises novel compds., their preparation and their pharmaceutical forms. The bioactivity of II was demonstrated. IT 241130-18-7P 241130-20-1P RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); EIS (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclic compds. as glycine transport inhibitors) RN 241130-18-7 CAPLUS CN 1-Piperidinebutanamide, 4-((cyclohexylphenylmethyl)amino)carbonyl-N,N-dimethyl- α,ω -diphenyl- (CA INDEX NAME)



RN 241130-20-1 CAPLUS
CN 1-Piperidinebutanamide, 4-((cyclohexylphenylmethyl)amino)carbonyl-N,N-dimethyl-

α,ω -diphenyl- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 1999:96124 CAPLUS

DOCUMENT NUMBER: 130:168242
TITLE: Preparation of 1-(4-sulfonamidobutyl)piperidines and related compounds as modulators of chemokine receptor activity.


INVENTOR(S): Caldwell, Charles G.; Finke, Paul E.; MacCoss, Malcolm; Meurer, Laura C.; Mills, Sander G.; Oates, Bryan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 281 pp.

CODEN: PIIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9904794	A1	19990204	WO 1998-US14990	19980721
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MW, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, ZA, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2296314	A1	19990204	CA 1998-2296314	19980721
AU 9885760	A	19990216	AU 1998-65760	19980721
EP 1003514	A1	20000531	EP 1998-936920	19980721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, IE, FI				
US 6136827	A	20001024	US 1998-120010	19980721
JP 2002510327	T	20020402	JP 1999-509949	19980721
PRIORITY APPLN. INFO.:			US 1997-53754P	P 19970725
			GB 1998-958	A 19980116
			WO 1998-US14990	W 19980721


OTHER SOURCE(S): MARPAT 130:168242
GI




AB Title compds. I (R1 = (substituted) alkyl; R2 = H, OH, alkyl, alkoxy, Ph, NMeCONHMe, NHCO2Me, Ac; R3 = aryl, aralkyl, aralkoxyalkyl, (substituted) aralkoxycarbonylamino, etc.) were prepared for treatment of AIDS (no data). Thus, N-(2-phenyl-4-oxobut-1-yl)-N-methylbenzenesulfonamide (preparation given) was stirred 20 min. with 4-phenylpiperidine, HOAc, and 3A mol. sieves in THF; Na triacetoxyborohydride was added and the mixture was kept 16 h to give N-(2-phenyl-4-(4-phenylpiperidin-1-yl)but-1-yl)-N-

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 methylbenzenesulfonamide hydrochloride.
 IT 220392-77-8P 220392-78-9P 220393-25-9P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 1-(4-sulfonamidobutyl)piperidines and related compds.

AB modulators of chemokine receptor activity)
 RN 220392-77-8 CAPLUS
 CN 4-Piperidinecarboxamide,
 1-(4-[methyl(phenoxy)sulfonyl]amino)-3-phenylbutyl)-N-pentyl- (CA INDEX NAME)




RN 220392-78-9 CAPLUS
 CN 4-Piperidinecarboxamide, N-(1-methylethyl)-1-(4-[methyl(phenoxy)sulfonyl]amino)-3-phenylbutyl)- (CA INDEX NAME)




RN 220393-25-9 CAPLUS
 CN 4-Piperidinecarboxamide,
 N,N-diethyl-1-(4-[methyl(phenoxy)sulfonyl]amino)-3-phenylbutyl- (CA INDEX NAME)

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220393-49-7 CAPLUS
 CN 4-Piperidinecarboxamide, N-(1,1-dimethylethyl)-1-(4-[methyl(phenoxy)sulfonyl]amino)-3-phenylbutyl- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:515956 CAPLUS
 DOCUMENT NUMBER: 129:225292
 TITLE: 4-Alkylpiperidines related to SR-48968: potent antagonists of the neurokinin-2 (NK2) receptor
 AUTHOR(S): Jacobs, Robert T.; Shenvi, Ashok B.; Mauger, Russell C.; Ulatowski, Terrance G.; Aharony, David; Buckner, Carl K.
 CORPORATE SOURCE: Department of Medicinal Chemistry, a Business Unit of ZENECA, Inc. ZENECA Pharmaceuticals, Wilmington, DE, 19850-5437, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1998), 8(14), 1935-1940
 CODEN: BMLC8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of 4-alkylpiperidine derivs. related to the potent neurokinin-2 (NK2) receptor antagonist SR-48968 (1) is described. Simple aliphatic derivs. were found to be poorly active, but appropriate placement of an alc. functional group afforded compds. that were of similar activity to 1. Several representatives in this series, such as the 4-(1-hydroxy-1-ethylpropyl)piperidine (14), were found to exhibit oral activity in a model of labored abdominal breathing in guinea pigs. These results expand the latitude of substituents available in this region of this series of NK2 receptor antagonists.
 IT 212910-73-1
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NK2 receptor antagonist activity of 4-Alkylpiperidines related to SR-48968)
 RN 212910-73-1 CAPLUS
 CN Benzamide, N-[4-(2-(acetylamino)ethyl)-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl- (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:346893 CAPLUS
 DOCUMENT NUMBER: 122:132987
 TITLE: Preparation of N-alkyl-substituted piperidines with neurokinin receptor antagonist activity.
 INVENTOR(S): Jacobs, Robert Toms; Shenvi, Ashok Kumar Bhikkappa
 PATENT ASSIGNEE(S): Zeneca Ltd., UK
 SOURCE: Eur. Pat. Appl., 27 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 625509	A1	19941123	EP 1994-303449	19940513
EP 625509	B1	19970730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE CA 2123636	A1	19941118	CA 1994-2123636	19940516
US 5521199	A	19960528	US 1994-242949	19940516
JP 06340624	A	19941213	JP 1994-137780	19940517
JP 3394819	B2	20030407		
PRIORITY APPLN. INFO.: GB 1993-10066 A 19930517				

OTHER SOURCE(S): MARPAT 122:132987
 GI




AB The title compds. (I; Q = (un)substituted Ph, (un)substituted thiienyl, (un)substituted imidazolyl, (un)substituted naphthyl, etc.; Q1 = H, Cl-3 alkyl or C3-6 cycloalkyl; * = an optional chiral center), useful as neurokinin 2 receptor antagonists, useful for the treatment of asthma (no data), are prepared and I-containing formulations presented. Thus, N-[2-(3,4-dichlorophenyl)-4-(2-(2-acetoxyethyl)piperidino)butyl]-N-methylbenzamide hydrochloride, m.p. 62-71°, was prepared from 4-(2-acetoxyethyl)piperidine and demonstrated Ki 40 nM to guinea pig-derived NKA receptors.

IT 160809-53-0
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-alkyl-substituted piperidines with neurokinin receptor antagonist activity)
 RN 160809-53-0 CAPLUS
 CN Benzamide, N-[4-(2-(acetylamino)ethyl)-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 160809-36-9P 160809-44-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of N-alkyl-substituted piperidines with neurokinin
 receptor
 antagonist activity)
 RN 160809-36-9 CAPLUS
 CN 4-Piperidinecarboxamide, 1-(4-(benzoylmethylamino)-3-(3,4-
 dichlorophenyl)butyl)-N-methoxy-N-methyl- (CA INDEX NAME)



RN 160809-44-9 CAPLUS
 CN 4-Piperidinecarboxamide, 1-(4-(benzoylmethylamino)-3-(3,4-
 dichlorophenyl)butyl)-N-methoxy-N-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 11:41:19 ON 04 FEB 2008)

FILE 'REGISTRY' ENTERED AT 11:41:29 ON 04 FEB 2008

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 37 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:42:04 ON 04 FEB 2008

L4 14 S L3 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	79.18	257.75
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.20	-11.20

STN INTERNATIONAL LOGOFF AT 11:45:55 ON 04 FEB 2008